Eli Lilly just added another win to retatrutide's growing clinical record. On March 19, 2026, the company announced topline results from TRANSCEND-T2D-1 — the first Phase 3 trial testing retatrutide in adults with type 2 diabetes. The triple-agonist delivered a 2.0% A1C reduction and 16.8% body weight loss at the 12 mg dose over 40 weeks, meeting all primary and key secondary endpoints. Weight loss had not plateaued by week 40, suggesting further reductions may be achievable with longer treatment.
This trial is separate from the TRIUMPH program that produced the 28.7% weight loss headline in obesity patients. TRANSCEND-T2D-1 focused specifically on glycemic control in type 2 diabetes — a different population, different primary endpoint, and a critical piece of the regulatory puzzle for retatrutide's eventual FDA filing.
Here's a full breakdown of the data and what it means.
What's New: TRANSCEND-T2D-1 at a Glance
TRANSCEND-T2D-1 is the first of several planned diabetes trials for retatrutide. It enrolled 537 adults with type 2 diabetes whose blood sugar was inadequately controlled on existing treatments.
| Parameter | Detail |
|---|---|
| Trial name | TRANSCEND-T2D-1 |
| Phase | Phase 3 |
| Duration | 40 weeks |
| Participants | 537 adults with type 2 diabetes |
| Design | Randomized, double-blind, placebo-controlled |
| Dose arms | 4 mg, 9 mg, 12 mg (once weekly) vs. placebo |
| Primary endpoint | Change in A1C from baseline |
| Baseline A1C | 7.9% (mean, all groups) |
| Baseline weight | 213.6 lbs / 96.9 kg (mean) |
| Baseline BMI | 35.8 kg/m² (mean) |
| Mean diabetes duration | 2.5 years |
The relatively early-stage diabetes population (mean duration 2.5 years) and moderate baseline A1C (7.9%) are worth noting. These are patients whose diabetes hasn't progressed to the point of requiring insulin — exactly the population where early intervention with a potent agent could change disease trajectory.
A1C Results: Superior Glycemic Control
Retatrutide delivered clinically meaningful A1C reductions across all three dose levels, with the strongest response at 9 mg.
| Dose | A1C Reduction | Final A1C (estimated) |
|---|---|---|
| 4 mg | -1.7% | ~6.2% |
| 9 mg | -2.0% | ~5.9% |
| 12 mg | -1.9% | ~6.0% |
| Placebo | -0.8% | ~7.1% |
A few things stand out:
The 9 mg dose matched the 12 mg dose. The 9 mg arm achieved a slightly larger A1C reduction (2.0% vs. 1.9%) than the 12 mg arm. This is an unusual but not unprecedented finding in diabetes trials — it may reflect a ceiling effect on glycemic control at these A1C levels, or statistical noise in a 40-week trial. Either way, it suggests that most of retatrutide's glycemic benefit is captured at the 9 mg dose.
Sub-6% A1C is within reach. At the 9 mg dose, the estimated final A1C of approximately 5.9% falls below the standard diabetes diagnostic threshold of 6.5%. In clinical terms, these patients were approaching non-diabetic blood sugar levels — a result that would represent functional remission for many.
Context matters. For comparison, tirzepatide (Mounjaro) achieved A1C reductions of 2.0-2.4% in the SURPASS program, and semaglutide (Ozempic) achieved approximately 1.5-1.8% in the SUSTAIN trials. Retatrutide's 2.0% reduction at 9 mg is competitive with tirzepatide and exceeds semaglutide, particularly impressive given the shorter 40-week duration of TRANSCEND-T2D-1.
Weight Loss in Diabetics: No Plateau in Sight
Weight loss in diabetes patients is typically more modest than in non-diabetic obesity patients, partly because insulin resistance and diabetes medications can promote weight retention. Against that backdrop, retatrutide's weight loss numbers in TRANSCEND-T2D-1 are notable.
| Dose | Weight Loss (%) | Weight Loss (lbs) | Weight Loss (kg) |
|---|---|---|---|
| 4 mg | 11.5% | 24.5 lbs | 11.1 kg |
| 9 mg | 15.5% | 33.3 lbs | 15.1 kg |
| 12 mg | 16.8% | 36.6 lbs | 16.6 kg |
| Placebo | 2.5% | 6.2 lbs | 2.8 kg |
The no-plateau finding is the headline within the headline. At week 40, weight loss was still trending downward in all retatrutide arms with no sign of leveling off. In most obesity and diabetes drug trials, weight loss begins to plateau around weeks 30-40. Retatrutide appears to defy that pattern — at least at the 40-week mark. If this trajectory continues in longer trials, final weight loss numbers could be substantially higher.
Diabetes patients are losing more than expected. For context, semaglutide (Ozempic 1.0 mg) produced approximately 5-7% weight loss in diabetes patients in the SUSTAIN trials. Tirzepatide (Mounjaro 15 mg) achieved approximately 12-13% in SURPASS-3. Retatrutide's 16.8% at 12 mg in a diabetes population — in just 40 weeks, without plateauing — significantly exceeds both benchmarks.
The glucagon receptor likely explains the difference. Retatrutide's third mechanism — glucagon receptor activation — increases energy expenditure and promotes fat oxidation independent of reduced food intake. This metabolic boost may explain why weight loss continues to accrue even after appetite suppression effects stabilize. It's the same mechanism that drove the 28.7% weight loss seen in the TRIUMPH-4 obesity trial.
Safety Profile: Familiar GI Side Effects
The adverse event profile in TRANSCEND-T2D-1 was consistent with the GLP-1 drug class and notably milder than what was seen in TRIUMPH-4.
| Adverse Event | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 16.2% | 22.1% | 26.5% | 3.7% |
| Diarrhea | 14.0% | 19.9% | 22.8% | 4.5% |
| Vomiting | 8.8% | 14.0% | 17.6% | 2.2% |
| Constipation | 10.3% | 12.5% | 15.4% | 3.0% |
Discontinuation rates were low. Treatment discontinuation due to adverse events ranged from 2.2% to 5.1% across retatrutide dose groups, compared to 0% in the placebo arm. These rates are considerably lower than the 12-18% discontinuation seen in TRIUMPH-4 — likely because the diabetes trial used a shorter duration and included a lower (4 mg) dose arm.
No dysesthesia signal reported. The TRIUMPH-4 obesity trial flagged dysesthesia (abnormal touch sensation) in up to 20.9% of participants at the 12 mg dose — a new safety finding that wasn't seen in Phase 2. In TRANSCEND-T2D-1, this side effect was not highlighted in the topline results. Whether this reflects a population-specific difference, dose-escalation differences, or simply didn't reach statistical significance in a 537-patient trial will require the full dataset publication to clarify.
How This Compares to TRIUMPH-4
TRANSCEND-T2D-1 and TRIUMPH-4 tested the same molecule but answered very different clinical questions.
| Parameter | TRIUMPH-4 (Obesity + Knee OA) | TRANSCEND-T2D-1 (Diabetes) |
|---|---|---|
| Population | Obesity/overweight + knee OA | Type 2 diabetes |
| Duration | 68 weeks | 40 weeks |
| Participants | 445 | 537 |
| Primary endpoint | Weight loss + WOMAC pain | A1C reduction |
| Max weight loss | 28.7% (12 mg) | 16.8% (12 mg) |
| A1C reduction | Not measured | 2.0% (9 mg) |
| Dysesthesia signal | Yes (20.9% at 12 mg) | Not reported |
| Discontinuation rate | 12-18% | 2.2-5.1% |
| Weight plateau? | Some leveling at ~60 weeks | No plateau at 40 weeks |
The lower weight loss in TRANSCEND is expected — diabetes patients typically lose less weight on the same drugs compared to non-diabetic patients. The more meaningful comparison is how retatrutide performed against other diabetes drugs in their own trials (see next section).
Retatrutide vs the Competition in Diabetes
Here's where retatrutide stands relative to the current diabetes treatment landscape:
| Drug | Mechanism | A1C Reduction | Weight Loss | Trial Duration | Status |
|---|---|---|---|---|---|
| Retatrutide (12 mg) | GLP-1 + GIP + Glucagon | 1.9% | 16.8% | 40 weeks | Phase 3 |
| Tirzepatide (Mounjaro 15 mg) | GLP-1 + GIP | 2.4% | 12.9% | 52 weeks | FDA-approved |
| Semaglutide (Ozempic 1.0 mg) | GLP-1 | 1.8% | 6.2% | 56 weeks | FDA-approved |
| Dulaglutide (Trulicity 1.5 mg) | GLP-1 | 1.5% | 3.0% | 52 weeks | FDA-approved |
A1C: Tirzepatide holds the edge in raw A1C reduction (2.4% in SURPASS), though retatrutide's 2.0% was achieved in a shorter 40-week trial with potentially more room to improve. Direct head-to-head trials would be needed for a definitive comparison.
Weight loss: Retatrutide leads clearly. Its 16.8% weight loss at 40 weeks — still trending downward — already exceeds tirzepatide's peak weight loss in diabetes patients and more than doubles semaglutide's. The glucagon receptor agonism appears to provide a meaningful metabolic advantage in this population.
Tolerability: Discontinuation rates for retatrutide (2.2-5.1%) were competitive with approved drugs. The absence of the dysesthesia signal in this trial is encouraging, though it needs confirmation across the broader TRANSCEND program.
Updated FDA Timeline
Today's data adds another piece to the retatrutide regulatory puzzle:
| Milestone | Expected Timeline |
|---|---|
| TRANSCEND-T2D-1 results | March 2026 (completed) |
| Remaining TRIUMPH trials (7 trials) | Throughout 2026 |
| Additional TRANSCEND diabetes trials | 2026-2027 |
| NDA filing (obesity) | Late 2026 |
| NDA filing (diabetes) | 2027 (estimated) |
| FDA decision (obesity) | Mid-2027 |
| FDA decision (diabetes) | 2027-2028 |
Lilly is now building a multi-indication submission strategy. The TRIUMPH program targets obesity (with comorbidities), while the TRANSCEND program targets type 2 diabetes. Both programs will generate distinct regulatory filings and, if approved, separate label indications — similar to how tirzepatide has separate approvals as Mounjaro (diabetes) and Zepbound (obesity).
Market analysts project retatrutide could generate $15.6 billion to $30 billion in annual sales by 2031, with the diabetes indication potentially representing the larger commercial opportunity given the global diabetes population of over 500 million.
What This Means for the Peptide Research Community
TRANSCEND-T2D-1 carries implications beyond Lilly's balance sheet.
The triple-agonist thesis keeps winning. Every new trial reinforces the core hypothesis: activating GLP-1, GIP, and glucagon receptors simultaneously produces metabolic benefits that dual-agonists and single-agonists cannot match. For the broader peptide research community, this validates continued investment in multi-receptor peptide design across therapeutic areas.
Diabetes expands the addressable market dramatically. Obesity drug trials get the splashy headlines, but type 2 diabetes affects over 500 million people globally — roughly 10x the eligible population for anti-obesity medications. Retatrutide's diabetes data positions it as a potential challenger to tirzepatide and semaglutide across both indications, which means more clinical attention, more research interest, and more capital flowing into peptide therapeutics broadly.
The "no plateau" finding could reshape treatment paradigms. If confirmed in longer trials, the absence of a weight loss plateau would challenge one of the most stubborn limitations of current obesity pharmacotherapy. Most drugs hit diminishing returns after 6-9 months. A drug that continues producing weight loss beyond that window — driven by the glucagon receptor's effect on basal energy expenditure — could fundamentally change how clinicians think about treatment duration and maintenance dosing.
What to Watch Next
The next 12 months will determine retatrutide's trajectory:
- TRIUMPH-1 results — The pivotal general obesity trial is expected in 2026 and will form the backbone of Lilly's FDA submission for the obesity indication.
- TRIUMPH-3 maintenance data — Tests a 4 mg maintenance dose that could reduce side effects while preserving weight loss, directly addressing concerns about the dysesthesia signal and treatment discontinuation.
- Additional TRANSCEND readouts — More diabetes trials will confirm whether today's A1C and weight loss results replicate across broader diabetes populations.
- Full TRANSCEND-T2D-1 publication — The complete dataset (expected at a major medical conference or in a peer-reviewed journal later in 2026) will reveal whether dysesthesia occurred in this trial at subclinical rates.
- Competitive landscape — Novo Nordisk's CagriSema (GLP-1 + amylin agonist) is advancing through its own Phase 3 program. How retatrutide stacks up against CagriSema in diabetes will shape the next chapter of the incretin drug wars.
This article will be updated as additional TRANSCEND and TRIUMPH Phase 3 data becomes available throughout 2026. For background on the TRIUMPH-4 obesity trial results, see our full breakdown of the 28.7% weight loss data.
PeptideWiki provides educational information about research peptides. This content is not medical advice. Always consult with a qualified healthcare provider before beginning any peptide protocol. See our full disclaimer for details.
